Kentucky Retirement Systems Has $3.51 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Kentucky Retirement Systems decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,860 shares of the medical research company’s stock after selling 792 shares during the quarter. Kentucky Retirement Systems’ holdings in IQVIA were worth $3,505,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new position in shares of IQVIA during the 4th quarter worth $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after acquiring an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC boosted its holdings in shares of IQVIA by 96.9% during the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after acquiring an additional 606,333 shares in the last quarter. Capital Research Global Investors grew its position in IQVIA by 42.2% during the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after acquiring an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP acquired a new position in IQVIA in the 4th quarter valued at approximately $70,108,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IQV. Morgan Stanley raised their target price on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Truist Financial lifted their price objective on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. UBS Group upped their target price on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Barclays raised their price target on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Finally, Evercore ISI upped their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $263.56.

IQVIA Stock Up 3.2 %

IQVIA stock traded up $7.38 during midday trading on Friday, reaching $239.67. The stock had a trading volume of 1,195,238 shares, compared to its average volume of 1,420,984. The company has a fifty day moving average price of $220.23 and a two-hundred day moving average price of $229.46. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.88 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $43.69 billion, a P/E ratio of 32.74, a PEG ratio of 2.26 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the previous year, the company posted $2.22 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.21 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.